What is the role of high-dose melphalan with autologous stem cell transplant (ASCT) in 2017? (https://www.myeloma.org/videos/role-high-dose-melphalan-autologous-stem-cell-transplant-asct-2017)
|
In this week’s video, Dr. Brian G.M. Durie discusses the value of ASCT even with the use of newer drug regimens. BOTTOM LINE:
|
|||
|
If you have a question that you’d like to suggest for a future episode of Ask Dr. Durie, please submit it to [email protected] (mailto:[email protected]). To reach the IMF InfoLine Coordinators, please call 800.452.2873 or email them at [email protected] (mailto:[email protected]). |
Dr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.